ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meeting Abstracts
    • All Meetings
    • ACR Convergence 2026
    • PRSYM 2026
    • ACR Convergence 2025
    • Download Abstract Supplements
  • Keyword Index
  • My Favorites
    • View & print my favorites
  • Search

ACR Convergence 2026

November 6-11, 2026. Orlando, Florida.

View by Number View by Title View Sessions
All • a b c d e f g h i j k l m n o p q r s t u [v] w x y z
  • Abstract Number: 2970
    Vaccination Knowledge, Attitudes, and Uptake Among Patients with Rheumatic Diseases Across Arabian Gulf Countries
  • Abstract Number: 1886
    Vaccine Effectiveness and Safety of Recombinant Zoster Vaccine in Psoriatic Arthritis Patients Aged 18 Years and Older
  • Abstract Number: 2538
    Vaccine Uptake and Attitudes Toward Adult Vaccination Among Patients with Autoimmune Inflammatory Rheumatic Diseases Receiving Biologic Therapy With or Without Conventional Synthetic DMARDs in Bahrain: A Cross-Sectional Study
  • Abstract Number: 1426
    Vagus-Mediated Neuroimmune Modulation for the Treatment of Rheumatoid Arthritis: Long-Term Results at 24 Months from a Randomized, Sham-Controlled, Double-Blind Trial
  • Abstract Number: 1364
    Validation of a Disease Activity Index for PSoriatic Arthritis Based on 44 Joints (DAPSA44) Using Data from Phase 3 Clinical Trials of Bimekizumab in Psoriatic Arthritis
  • Abstract Number: 2191
    Validation of anti-C1q, anti-dsDNA, and anti-Sm antibodies as reliable biomarkers for identifying lupus nephritis using a large real-world cohort of 62,734 patients
  • Abstract Number: 1916
    Validation of Cutaneous Lupus Erythematosus Disease Area and Severity Index-Activity (CLASI-A) for Evaluation of Patients with Cutaneous Lupus Erythematosus in Clinical Trials
  • Abstract Number: 2151
    Validation of Glucocorticoid Toxicities Experienced During Treatment of Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: A Simulation Modeling Approach
  • Abstract Number: 2380
    Validation of ICD Diagnosis-Based and Large Language Model-Based Approaches to Identify Patients With Moderate to Severe Sjögren’s Disease
  • Abstract Number: 0644
    Validation of Markerless Motion Capture to Assess Physical Function in Knee Osteoarthritis
  • Abstract Number: 2808
    Validation of New Clinical Thresholds for Low Inflammatory Activity using Modified Disease Activity Scores in Rheumatoid Arthritis
  • Abstract Number: 1013
    Validation of Serum Cytokines During Pregnancy In Systemic Lupus Erythematosus
  • Abstract Number: 1365
    Validation of the Disease Activity Index for Psoriatic Arthritis Based on 44 Joints (DAPSA44) in Axial and Peripheral Spondyloarthritis: Evidence from 3 Randomised Controlled Trials
  • Abstract Number: 1811
    Validity of Fitbit Inspire 2 Activity Metrics in Adults after Knee Replacement
  • Abstract Number: 0668
    Validity of Functional Tests as Outcome Measures in Idiopathic Inflammatory Myopathies: Functional Index-3 (FI-3), Sit-to-Stand Test in 30 seconds (STS), and Timed Up and Go (TUG)
  • Abstract Number: 1396
    Variation in Pulmonary Complications amongst Primary Sjögren’s Syndrome Patients with Distinct Serological Profiles
  • Abstract Number: 0191
    Vascular Complications and Clinical Outcomes in Giant Cell Arteritis Patients with Indeterminate Temporal Artery Biopsy Results
  • Abstract Number: 0090
    Vascular Inflammation Drives Synovial Fibroblast Expansion and Remodelling In Rheumatoid Arthritis
  • Abstract Number: 0091
    Vascularized Synovium-on-a-Chip – a Patient-Derived Rheumatoid Arthritis Model that Mimics Disease, Biological Heterogeneity, and Actual Treatment Response
  • Abstract Number: 1171
    Vasculitis Relapse in Patients with Eosinophilic Granulomatosis with Polyangiitis. Prospective Data from a Clinical Trial
  • Abstract Number: 0056
    VE-cadherin: a potential marker of ongoing glomerular endothelial injury and future target in lupus nephritis
  • Abstract Number: 2905
    VERANDA™-SSc: Design of a Phase III, Double-blind, Randomized, Placebo-controlled Trial Evaluating the Safety and Efficacy of Oral Nerandomilast Treatment on Halting Disease Progression in Systemic Sclerosis
  • Abstract Number: 0704
    VEXAS Syndrome Identified in a Tertiary Rheumatology Center: A Case Series
  • Abstract Number: 1085
    Vimentin Modified with Malondialdehyde-Acetaldehyde Increases Lung Collagen Levels following Injection in DBA/1J Mice
  • Abstract Number: 0127
    Viral Remodeling of the MHC Class II Immunopeptidome Exposes SLE-Associated Autoantigens
  • Abstract Number: 0798
    Virtual rheumatology visits are associated with decreased odds of treatment changes for rheumatoid arthritis patients: a retrospective cohort study
  • Abstract Number: 0439
    Vitamin A deficiency in primary Sjögren’s disease
  • Abstract Number: 0287
    Voclosporin vs. Belimumab in Lupus Nephritis: Two-Year Renal Outcomes in a Retrospective Propensity Score-Matched Real-World Cohort
All • a b c d e f g h i j k l m n o p q r s t u [v] w x y z

My Favorites

Save and print abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract (must have cookies enabled in browser). See saved favorites.

Abstract Policies

  • ACR Convergence Abstract Embargo Policies
  • ACR Convergence Abstract Permissions & Reprints
  • PRSYM Abstract Policies

ACR Convergence. Where Rheumatology Meets

ACR Convergence 2026

Join us November 6-11 in Orlando, Florida.
See Registration Information

  • Contact ACR
  • Privacy Policy
  • ACR Policies
  • Cookie Preferences

© Copyright 2026 American College of Rheumatology